Our CRO services in cardiovascular disease (CVD)

Investigate the efficacy of your potential novel agents in
rodent models of cardiovascular disease (CVD).

LAD-ligation mouse model

  • Transient or permanent ligation of left anterior descending (LAD) artery.
  • Cardiac hypertrophy and pump dysfunction alleviated by  Angiotensin-converting-enzyme inhibitors.
  • 2- and 3-dimensional evaluation of cardiac function and morphology.
See data
Posters

Isoprenaline-induced cardiac fibrosis

  • Reduced cardiac function and marked subendocardial fibrosis.
  • Preventive or therapeutic study design.
  • Evaluation of functional and morphological changes using echocardiography and telemetry.
See data
Publications

Contact us to hear more about our other relevant rodent models of cardiovascular disease such as the ones below.

Angiotensin II infusion model

  • Angiotensin II delivered by subcutaneous osmotic pumps for 2-4 weeks
  • Cardiac hypertrophy and fibrosis
  • Heart failure with preserved ejection fraction

ReninAAV Unx db/db model (heart)

  • Hypertensive, type 2 diabetic mouse model of diabetic cardio-renal syndrome
  • Adeno-associated virus-induced hypertension in uninephrectomized db/db mice
  • Progressive albuminuria and loss of kidney function
  • Cardiac hypertrophy

Atherosclerosis model

  • Genetically modified mouse models (ApoE-/- or LDL r-/-) on western diet
  • Hypercholesterolemia
  • Obesity and glucose intolerance
  • Plaque volume quantification and composition incl. 3D spatial mapping
  • “En face” plaque area quantification of the aortic arch using Oil-Red-O staining​

Straight to the heart of the matter.

Gubra offers pharmaceutical research and comprehensive in vivo readouts in diverse cardiovascular disease models. With 3D imaging we can quantify and measure the size of heart infarction and several other endpoints in any relevant heart disease model.

Fully equipped platform for cardiovascular characterization

We have a unique combination of state-of-the art in vivo, ex vivo and in vitro methodologies that can be individually combined to evaluate drug efficacy in cardiovascular diseases.

We have several established models of HFrEF. The study design can be modified to meet your exact needs.

 

Related Links:

Main offerings

 

  • State-of-the art echocardiography using a high-resolution imaging platform incl. assessment of cardiac function in 2D, 4D and strain imaging.
  • Wireless chronic acquisition of electrocardiography (ECG) using telemetry.
  • Histological evaluation of fibrotic and arteriosclerotic changes in the myocardium.
  • 3D imaging of the intact mouse heart incl. quantification of cardiac wall and cavity volumes, infarct volume and capillary density.
  • Single-cell and bulk myocardial RNA sequencing.
  • Measurement of clinically-relevant plasma markers of cardiomyocyte damage and stretch.

Get in touch

Please get in touch if you are interested in discussing how to get started with your study.

Niels Vrang

Co-founder, Chairman of the board

niels@gubra.dk
+45 3152 2651

© 2020 Gubra